Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR5 | P51681 | 2/20 | 0.46 |
| ▸ | NPY2R | P49146 | 1/20 | 0.45 |
| ▸ | BACE1 | P56817 | 1/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
| ▸ | TRPM2 | O94759 | 1/20 | 0.42 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | PPARG | P37231 | 1/20 | 0.42 |
| ▸ | TACR1 | P25103 | 3/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14282927 | 0.90 | BACE1 (0.52) | NPY2RBACE1KDM4EALDH1A1 | |
| SCHEMBL3658957 | 0.89 | ALDH1A1 (0.47) | CCR5TRPM2OPRK1CYP2D6KDM4E | |
| SCHEMBL3661573 | 0.86 | BACE1 (0.49) | CCR5BACE1KCNH2TACR1 | |
| SCHEMBL3664104 | 0.80 | CCR5 (0.47) | CCR5BACE1OPRK1CYP2D6TACR1 | |
| SCHEMBL14282940 | 0.78 | ALDH1A1 (0.52) | NPY2RKDM4EALDH1A1 | |
| SCHEMBL7359674 | 0.77 | ALDH1A1 (0.55) | NPY2RBACE1CYP2D6KDM4EALDH1A1 | |
| SCHEMBL3663874 | 0.76 | SLC6A9 (0.53) | BACE1OPRK1TACR1 | |
| SCHEMBL9353069 | 0.75 | BCHE (0.56) | KCNH2OPRK1CYP2D6 | |
| SCHEMBL11609412 | 0.75 | TACR1 (0.47) | CCR5BACE1OPRK1TACR1 | |
| SCHEMBL3664457 | 0.74 | OPRM1 (0.50) | OPRK1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8258306-B2 | Glycine transporter-1 inhibitors | AMGEN INC. (US) | 2012-09-04 | — | — | US | disclosed |
| US-20100298341-A1 | Glycine Transporter-1 Inhibitors | AMGEN INC. | 2010-11-25 | — | — | US | disclosed |
| EP-2231601-A2 | GLYCINE TRANSPORTER-1 INHIBITORS | Amgen, Inc (US) | 2010-09-29 | — | — | EP | disclosed |
| WO-2009075857-A2 | GLYCINE TRANSPORTER-1 INHIBITORS | AMGEN INC. (US) | 2009-06-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298341-A1 | Glycine Transporter-1 Inhibitors | SLC18A2, SLC7A11, SLC6A5 | CCR5 2040/4885NPY2R 2974/4885BACE1 201/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.